Dyadic International Reports Operational and Commercial Progress in Q1 2026 Earnings Call
During its Q1 2026 earnings call, Dyadic (DYAI) highlighted ongoing operational progress as it transitions from a platform technology company to a commercial biotechnology firm. The company emphasized the launch of products enabled by its microbial production platforms and multiple revenue streams through direct sales, partnerships, and licensing.
Topics: biotechnology commercial progress revenue generation